Raluca Zaharia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Raluca Zaharia has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Gabriel Mihail Dimofte
Grigore T Popa University of Medicine and Pharmacy, 700115 Iasi, Romania
7 shared publications - Sorinel Lunca
Grigore T Popa University of Medicine and Pharmacy, 700115 Iasi, Romania
7 shared publications - Stefan Morarasu
Grigore T Popa University of Medicine and Pharmacy, 700115 Iasi, Romania
7 shared publications - Wee Liam Ong
Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania
6 shared publications - Ana Maria Musina
Grigore T Popa University of Medicine and Pharmacy, 700115 Iasi, Romania
2 shared publications - Ana-Maria Muşină
Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania
2 shared publications
Latest Publications
- Open Access
- 14 July 2026
- Published by MDPI AG in Medical Sciences
- Vol. 14 (3) , 393
Total Neoadjuvant Therapy Versus Long-Course Chemoradiotherapy in Locally Advanced Rectal Cancer: Real-World Tumor Response and Clinical Outcomes
Background: Total neoadjuvant therapy is becoming a preferred option for locally advanced rectal cancer, particularly in patients with high-risk baseline features. However, real-world evidence comparing tumor response, MRI-defined high-risk feature clearance, surgical outcomes, and survival after total neoadjuvant therapy versus conventional long-course chemoradiotherapy remains limited. This study aimed to compare outcomes between total neoadjuvant therapy and long-course chemoradiotherapy in patients with locally advanced rectal cancer treated in routine clinical practice. Methods: This is a retrospective, single-centre cohort study focused on patients with stage II–III locally advanced rectal adenocarcinoma treated with curative-intent neoadjuvant therapy using either total neoadjuvant therapy or long-course chemoradiotherapy. Tumor response was assessed using restaging MRI, clinical complete response, and pathological complete response. Surgical outcomes and overall survival were evaluated. Results: A total of 110 patients were included. Patients treated with total neoadjuvant therapy had a higher baseline disease burden reflected by a greater proportion of cT4 tumors (40.6% vs. 19.2%; p = 0.014). Radiologic tumor-length response and clearance of MRI-defined high-risk features were comparable between treatment strategies. Clinical and pathological complete response rates were numerically higher in the total neoadjuvant therapy group, but the differences were not significant (cCR: 15.6% vs. 6.4%, p = 0.151; pCR: 18.5% vs. 9.7%, p = 0.301). Conclusions: In this real-world cohort, TNT was preferentially used in patients with more advanced baseline disease and showed numerically higher complete response rates, although differences were not statistically significant. Radiologic response, surgical outcomes, and short-term survival were comparable between treatment strategies. These findings support the feasibility of TNT in routine clinical practice but should be interpreted as exploratory and hypothesis-generating rather than evidence of treatment superiority.
- 14 July 2026
- Published by MDPI AG in Medical Sciences
- Vol. 14 (3) , 393
Open AccessTotal Neoadjuvant Therapy Versus Long-Course Chemoradiotherapy in Locally Advanced Rectal Cancer: Real-World Tumor Response and Clinical Outcomes
Background: Total neoadjuvant therapy is becoming a preferred option for locally advanced rectal cancer, particularly in patients with high-risk baseline features. However, real-world evidence comparing tumor response, MRI-defined high-risk feature clearance, surgical outcomes, and survival after total neoadjuvant therapy versus conventional long-course chemoradiotherapy remains limited. This study aimed to compare outcomes between total neoadjuvant therapy and long-course chemoradiotherapy in patients with locally advanced rectal cancer treated in routine clinical practice. Methods: This is a retrospective, single-centre cohort study focused on patients with stage II–III locally advanced rectal adenocarcinoma treated with curative-intent neoadjuvant therapy using either total neoadjuvant therapy or long-course chemoradiotherapy. Tumor response was assessed using restaging MRI, clinical complete response, and pathological complete response. Surgical outcomes and overall survival were evaluated. Results: A total of 110 patients were included. Patients treated with total neoadjuvant therapy had a higher baseline disease burden reflected by a greater proportion of cT4 tumors (40.6% vs. 19.2%; p = 0.014). Radiologic tumor-length response and clearance of MRI-defined high-risk features were comparable between treatment strategies. Clinical and pathological complete response rates were numerically higher in the total neoadjuvant therapy group, but the differences were not significant (cCR: 15.6% vs. 6.4%, p = 0.151; pCR: 18.5% vs. 9.7%, p = 0.301). Conclusions: In this real-world cohort, TNT was preferentially used in patients with more advanced baseline disease and showed numerically higher complete response rates, although differences were not statistically significant. Radiologic response, surgical outcomes, and short-term survival were comparable between treatment strategies. These findings support the feasibility of TNT in routine clinical practice but should be interpreted as exploratory and hypothesis-generating rather than evidence of treatment superiority.
- Open Access
- 13 November 2025
- Published by MDPI AG in Medical Sciences
- Vol. 13 (4) , 267
Individualized Risk Prediction of Medical Postoperative Complications After Oncologic Hepatectomy: A Nomogram-Based Approach
Background: Liver resection remains the primary curative treatment for many malignant liver diseases. Advances in patient selection, perioperative care, and surgical technique have markedly reduced procedure-related (surgical) complications in experienced centres. However, despite these improvements, medical (non-surgical) complications continue to represent a substantial source of postoperative morbidity, particularly after major liver resections. Herein, we aim to assess the incidence, nature, and predictors of medical versus surgical complications after liver resection and to develop an individual risk calculator for estimating medical morbidity after liver resection. Methods: This is an observational single-centre study including patients who underwent liver resection for cancer between 2013 and 2025. Postoperative complications were classified into medical and surgical categories based on clinical and diagnostic criteria. Demographic, clinical, and intraoperative data were analyzed to identify risk factors associated with each type of complication, and a multivariate logistic regression model was used to select significant variables, which were imputed in a prediction nomogram made available as an interactive web-based calculator. Results: Of the 231 patients included, 36 patients (15.6%) developed postoperative complications. From multivariate analysis, independent predictors of medical complications included cirrhosis (OR 2.8, 95% CI 1.2–6.8, p < 0.05), operative time > 180 min (OR 2.0, 95% CI 1.1–7.4, p < 0.05), intraoperative blood loss > 500 mL (OR 2, 95% CI: 0.9–4.8, p < 0.05), and ASA score ≥ 3 (OR 3.7, 95% CI 1.1–12.5, p < 0.05). Major hepatic resection was the only independent predictor of surgical complications (OR 7.42, 95% CI: 1.14–48.52, p = 0.036). The logistic regression model demonstrated fair discriminative ability with an AUC of 0.682 (95% CI: 0.544–0.729). The risk-prediction nomogram showed a 24.7% risk of postoperative medical morbidity in patients with all four risk factors vs. a 5.4% risk in patients without any risk factor. Conclusion: Postoperative medical complications are significantly more frequent in patients undergoing oncological liver resection with an ASA score ≥ 3, history of cirrhosis, prolonged operative time, and increased intraoperative blood loss. Our logistic regression model and web-friendly nomogram may be used for external validation in larger cohorts and could support preoperative counselling and perioperative risk stratification.
- 13 November 2025
- Published by MDPI AG in Medical Sciences
- Vol. 13 (4) , 267
Open AccessIndividualized Risk Prediction of Medical Postoperative Complications After Oncologic Hepatectomy: A Nomogram-Based Approach
Background: Liver resection remains the primary curative treatment for many malignant liver diseases. Advances in patient selection, perioperative care, and surgical technique have markedly reduced procedure-related (surgical) complications in experienced centres. However, despite these improvements, medical (non-surgical) complications continue to represent a substantial source of postoperative morbidity, particularly after major liver resections. Herein, we aim to assess the incidence, nature, and predictors of medical versus surgical complications after liver resection and to develop an individual risk calculator for estimating medical morbidity after liver resection. Methods: This is an observational single-centre study including patients who underwent liver resection for cancer between 2013 and 2025. Postoperative complications were classified into medical and surgical categories based on clinical and diagnostic criteria. Demographic, clinical, and intraoperative data were analyzed to identify risk factors associated with each type of complication, and a multivariate logistic regression model was used to select significant variables, which were imputed in a prediction nomogram made available as an interactive web-based calculator. Results: Of the 231 patients included, 36 patients (15.6%) developed postoperative complications. From multivariate analysis, independent predictors of medical complications included cirrhosis (OR 2.8, 95% CI 1.2–6.8, p < 0.05), operative time > 180 min (OR 2.0, 95% CI 1.1–7.4, p < 0.05), intraoperative blood loss > 500 mL (OR 2, 95% CI: 0.9–4.8, p < 0.05), and ASA score ≥ 3 (OR 3.7, 95% CI 1.1–12.5, p < 0.05). Major hepatic resection was the only independent predictor of surgical complications (OR 7.42, 95% CI: 1.14–48.52, p = 0.036). The logistic regression model demonstrated fair discriminative ability with an AUC of 0.682 (95% CI: 0.544–0.729). The risk-prediction nomogram showed a 24.7% risk of postoperative medical morbidity in patients with all four risk factors vs. a 5.4% risk in patients without any risk factor. Conclusion: Postoperative medical complications are significantly more frequent in patients undergoing oncological liver resection with an ASA score ≥ 3, history of cirrhosis, prolonged operative time, and increased intraoperative blood loss. Our logistic regression model and web-friendly nomogram may be used for external validation in larger cohorts and could support preoperative counselling and perioperative risk stratification.
- Open Access
- 31 October 2025
- Published by MDPI AG in Medical Sciences
- Vol. 13 (4) , 253
Should We Fear the Frail? A Review on the Impact of Frailty on Liver Surgery
Background: Frailty is a multidimensional syndrome characterized by reduced physiological reserve and resilience and has become a crucial predictor of outcomes in liver surgery. Unlike chronological age, frailty reflects broader vulnerabilities that significantly influence postoperative recovery. Aim: To review and synthesize current evidence on the relationship between frailty and postoperative outcomes following liver resection, with an emphasis on short-term complications, mortality, and long-term survival. Methods: A comprehensive literature review was performed, drawing on recent meta-analyses, large-scale cohort studies, and prospective observational data. Frailty was evaluated using a range of assessment tools, including the Modified Frailty Index (mFI), Clinical Frailty Scale (CFS), Kihon Checklist (KCL), and claims-based measures such as the Johns Hopkins Frailty Indicator. Results: Across studies, frailty has been consistently linked to a higher incidence of postoperative complications, such as post-hepatectomy liver failure (PHLF), infections, extended hospital stays, and increased mortality. In patients undergoing liver resection for cancer, frailty is also associated with poorer long-term survival. Importantly, frailty serves as an independent risk factor, even after adjusting for age, comorbid conditions, and tumor characteristics. Preoperative identification of frailty enhances risk stratification, informs surgical planning, potentially favoring parenchymal-sparing or minimally invasive approaches, and highlights patients who may benefit from prehabilitation. Conclusions: Frailty is a strong and independent predictor of poor outcomes after liver resection. Incorporating frailty assessment into routine preoperative evaluation can improve surgical decision-making, facilitate informed patient counseling, and optimize perioperative care strategies.
- 31 October 2025
- Published by MDPI AG in Medical Sciences
- Vol. 13 (4) , 253
Open AccessShould We Fear the Frail? A Review on the Impact of Frailty on Liver Surgery
Background: Frailty is a multidimensional syndrome characterized by reduced physiological reserve and resilience and has become a crucial predictor of outcomes in liver surgery. Unlike chronological age, frailty reflects broader vulnerabilities that significantly influence postoperative recovery. Aim: To review and synthesize current evidence on the relationship between frailty and postoperative outcomes following liver resection, with an emphasis on short-term complications, mortality, and long-term survival. Methods: A comprehensive literature review was performed, drawing on recent meta-analyses, large-scale cohort studies, and prospective observational data. Frailty was evaluated using a range of assessment tools, including the Modified Frailty Index (mFI), Clinical Frailty Scale (CFS), Kihon Checklist (KCL), and claims-based measures such as the Johns Hopkins Frailty Indicator. Results: Across studies, frailty has been consistently linked to a higher incidence of postoperative complications, such as post-hepatectomy liver failure (PHLF), infections, extended hospital stays, and increased mortality. In patients undergoing liver resection for cancer, frailty is also associated with poorer long-term survival. Importantly, frailty serves as an independent risk factor, even after adjusting for age, comorbid conditions, and tumor characteristics. Preoperative identification of frailty enhances risk stratification, informs surgical planning, potentially favoring parenchymal-sparing or minimally invasive approaches, and highlights patients who may benefit from prehabilitation. Conclusions: Frailty is a strong and independent predictor of poor outcomes after liver resection. Incorporating frailty assessment into routine preoperative evaluation can improve surgical decision-making, facilitate informed patient counseling, and optimize perioperative care strategies.
- Open Access
Clostridium difficile Colonization in Oncologic Patients Undergoing Major Abdominopelvic Surgery: To Treat or Not to Treat? An Observational Study with Propensity Score Analysis
Background: Clostridium difficile colonization (CDC) represents a clinical concern in oncology patients undergoing abdominopelvic surgery, particularly regarding the potential role of prophylactic antibiotics in preventing progression to active infection. Methods: We performed a single-center, retrospective, case-matched observational study of oncology patients with CDC who underwent abdominopelvic surgery between 2018 and 2023. Patients were divided into two cohorts: those who received prophylactic antibiotics and those who did not. Postoperative outcomes were compared using propensity score matching (PSM). Logistic regression and ROC curve analysis were applied to assess the predictive value of antibiotics relative to other comorbidities. Results: Ninety patients were included (62 with antibiotics; 28 without). In the unmatched cohort, patients receiving antibiotics showed a non-significant trend toward higher morbidity (32.2% vs. 21.4%, p = 0.327) and surgical site infection rates (9.6% vs. 0%, p = 0.171). After PSM (26 patients per group), morbidity remained comparable between cohorts (30.7% vs. 23.0%, p = 0.538). Notably, no patient developed active C. difficile infection during follow-up, regardless of antibiotic use. Antibiotic therapy was not an independent predictor of postoperative morbidity (OR 1.746, p = 0.297; AUC 0.549, 95% CI 0.405–0.687). Conclusions: In this study, prophylactic antibiotic use in CDC patients undergoing abdominopelvic oncology surgery was not associated with improved postoperative outcomes. While no progression to active infection was observed, the potential benefits of prophylaxis remain uncertain. Larger, prospective studies are needed to clarify the clinical role of antibiotics in this setting.
Open AccessClostridium difficile Colonization in Oncologic Patients Undergoing Major Abdominopelvic Surgery: To Treat or Not to Treat? An Observational Study with Propensity Score Analysis
Background: Clostridium difficile colonization (CDC) represents a clinical concern in oncology patients undergoing abdominopelvic surgery, particularly regarding the potential role of prophylactic antibiotics in preventing progression to active infection. Methods: We performed a single-center, retrospective, case-matched observational study of oncology patients with CDC who underwent abdominopelvic surgery between 2018 and 2023. Patients were divided into two cohorts: those who received prophylactic antibiotics and those who did not. Postoperative outcomes were compared using propensity score matching (PSM). Logistic regression and ROC curve analysis were applied to assess the predictive value of antibiotics relative to other comorbidities. Results: Ninety patients were included (62 with antibiotics; 28 without). In the unmatched cohort, patients receiving antibiotics showed a non-significant trend toward higher morbidity (32.2% vs. 21.4%, p = 0.327) and surgical site infection rates (9.6% vs. 0%, p = 0.171). After PSM (26 patients per group), morbidity remained comparable between cohorts (30.7% vs. 23.0%, p = 0.538). Notably, no patient developed active C. difficile infection during follow-up, regardless of antibiotic use. Antibiotic therapy was not an independent predictor of postoperative morbidity (OR 1.746, p = 0.297; AUC 0.549, 95% CI 0.405–0.687). Conclusions: In this study, prophylactic antibiotic use in CDC patients undergoing abdominopelvic oncology surgery was not associated with improved postoperative outcomes. While no progression to active infection was observed, the potential benefits of prophylaxis remain uncertain. Larger, prospective studies are needed to clarify the clinical role of antibiotics in this setting.
- Open Access
- 26 May 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (11) , 1334
Can We Achieve More with Less? Parenchymal Sparing Surgery Versus Major Liver Resection for Colorectal Liver Metastases: An Observational Single-Center Study with Propensity Score Analysis
Background/Objectives: Colorectal liver metastases (CRLMs) occur in 25–30% of colorectal cancer (CRC) patients, significantly impacting survival. While major liver resection (MLR) was traditionally preferred for oncologic clearance, parenchymal-sparing surgery (PSS) has emerged as a less invasive alternative. This study compares perioperative and long-term outcomes of PSS versus MLR in CRLM patients. Methods: We conducted a retrospective cohort study at the Regional Oncology Institute, Iasi, Romania, analyzing patients who underwent hepatic resection for CRLM between August 2013 and June 2024. Patients were categorized into PSS (n = 58) and MLR (n = 28) groups. Outcomes assessed included perioperative parameters, postoperative morbidity, overall survival (OS), and disease-free survival (DFS). Results: PSS was associated with a shorter operative time (235.2 vs. 302.6 min, p = 0.003), lower morbidity (18.9% vs. 57.1%, p = 0.001), and fewer major complications (Clavien–Dindo ≥ III, p = 0.005). ICU stay was significantly longer in MLR patients (p = 0.04). After propensity score matching (PSM), PSS was found to have lower morbidity compared to MLR (p = 0.023) with similar major morbidity (p = 0.473) and LOS (p = 0.579). Overall survival (31 vs. 37.1 months, p = 0.884) and disease-free survival (25.2 vs. 22.2 months, p = 0.519) were comparable between the groups before and after propensity score matching PSM (40.9 vs. 21.2 months, p = 0.741 and 24.3 vs. 13.8 months, p = 0.653). Conclusions: PSS achieves comparable oncologic outcomes to MLR while reducing postoperative morbidity and ICU stay. These findings support PSS as the preferred approach for CRLM, reserving MLR for select cases requiring extensive resection.
- 26 May 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (11) , 1334
Open AccessCan We Achieve More with Less? Parenchymal Sparing Surgery Versus Major Liver Resection for Colorectal Liver Metastases: An Observational Single-Center Study with Propensity Score Analysis
Background/Objectives: Colorectal liver metastases (CRLMs) occur in 25–30% of colorectal cancer (CRC) patients, significantly impacting survival. While major liver resection (MLR) was traditionally preferred for oncologic clearance, parenchymal-sparing surgery (PSS) has emerged as a less invasive alternative. This study compares perioperative and long-term outcomes of PSS versus MLR in CRLM patients. Methods: We conducted a retrospective cohort study at the Regional Oncology Institute, Iasi, Romania, analyzing patients who underwent hepatic resection for CRLM between August 2013 and June 2024. Patients were categorized into PSS (n = 58) and MLR (n = 28) groups. Outcomes assessed included perioperative parameters, postoperative morbidity, overall survival (OS), and disease-free survival (DFS). Results: PSS was associated with a shorter operative time (235.2 vs. 302.6 min, p = 0.003), lower morbidity (18.9% vs. 57.1%, p = 0.001), and fewer major complications (Clavien–Dindo ≥ III, p = 0.005). ICU stay was significantly longer in MLR patients (p = 0.04). After propensity score matching (PSM), PSS was found to have lower morbidity compared to MLR (p = 0.023) with similar major morbidity (p = 0.473) and LOS (p = 0.579). Overall survival (31 vs. 37.1 months, p = 0.884) and disease-free survival (25.2 vs. 22.2 months, p = 0.519) were comparable between the groups before and after propensity score matching PSM (40.9 vs. 21.2 months, p = 0.741 and 24.3 vs. 13.8 months, p = 0.653). Conclusions: PSS achieves comparable oncologic outcomes to MLR while reducing postoperative morbidity and ICU stay. These findings support PSS as the preferred approach for CRLM, reserving MLR for select cases requiring extensive resection.
- Open Access
- 19 April 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (8) , 2831
Predictive Risk Factors for Low Anterior Resection Syndrome (LARS) in Rectal Cancer—An Observational Cohort Study
Background/Objectives: The improved long-term survival of rectal cancer patients has led to a major increase in the prevalence of functional complications. Understanding which patients are prone to develop major LARS is important for their preoperative counselling and follow-up. Herein, we aimed to assess the risk factors for LARS. Methods: This is a retrospective cohort study on rectal cancer patients. All patient and tumour variables, management plan, type of neoadjuvant therapy, radiation dose to anal sphincter, and perioperative outcomes were collected from the hospital electronic databases. We quantified LARS and compared the score before and after surgery (mean follow-up of 42.2 ± 32 months). Results: A total of 182 patients were included for the final analysis. LARS was present in 43.4% (n = 79) of patients, with 14.8% (n = 27) having minor LARS and 28.5% (n = 52) having major LARS. Age (p = 0.03), male gender (p < 0.00001), smoking (p = 0.04), neoadjuvant radiotherapy (p = 0.02), rectal stump length (p = 0.008), end-to-end anastomosis (p = 0.008), and ileostomy (p = 0.002) were found to significantly increase the rate of LARS. A logistic regression model based on the above variables was able to predict major LARS with good predictive value (AUC 0.700). Conclusions: LARS is highly common after sphincter-preserving surgery, and it is significantly more common in young, male patients with a history of smoking, having mid-lower rectal cancers with neoadjuvant radiotherapy, and undergoing TME surgery with end-to-end low anastomosis and ileostomy.
- 19 April 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (8) , 2831
Open AccessPredictive Risk Factors for Low Anterior Resection Syndrome (LARS) in Rectal Cancer—An Observational Cohort Study
Background/Objectives: The improved long-term survival of rectal cancer patients has led to a major increase in the prevalence of functional complications. Understanding which patients are prone to develop major LARS is important for their preoperative counselling and follow-up. Herein, we aimed to assess the risk factors for LARS. Methods: This is a retrospective cohort study on rectal cancer patients. All patient and tumour variables, management plan, type of neoadjuvant therapy, radiation dose to anal sphincter, and perioperative outcomes were collected from the hospital electronic databases. We quantified LARS and compared the score before and after surgery (mean follow-up of 42.2 ± 32 months). Results: A total of 182 patients were included for the final analysis. LARS was present in 43.4% (n = 79) of patients, with 14.8% (n = 27) having minor LARS and 28.5% (n = 52) having major LARS. Age (p = 0.03), male gender (p < 0.00001), smoking (p = 0.04), neoadjuvant radiotherapy (p = 0.02), rectal stump length (p = 0.008), end-to-end anastomosis (p = 0.008), and ileostomy (p = 0.002) were found to significantly increase the rate of LARS. A logistic regression model based on the above variables was able to predict major LARS with good predictive value (AUC 0.700). Conclusions: LARS is highly common after sphincter-preserving surgery, and it is significantly more common in young, male patients with a history of smoking, having mid-lower rectal cancers with neoadjuvant radiotherapy, and undergoing TME surgery with end-to-end low anastomosis and ileostomy.
- Open Access
- 20 February 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (5) , 512
Is Frailty Associated with Worse Outcomes After Major Liver Surgery? An Observational Case–Control Study
Background: The rate of morbidity after liver surgery is estimated at 30% and can be even higher when considering higher-risk subgroups of patients. Frailty is believed to better predict surgical outcomes by showcasing the patient’s ability to withstand major surgical stress and selecting frail ones. Methods: This is a single-centre, observational case–control study on patients diagnosed with liver malignancies who underwent liver resections between 2013 and 2024. The five-item modified Frailty Index (mFI-5) was used to split patients into frail and non-frail. The two groups were compared in terms of preoperative, operative and postoperative outcomes using a chi-squared and logistic regression model. Results: A total of 230 patients were included and split into two groups: non-frail, NF, n = 90, and frail patients, F, n = 140. Overall, F patients had a higher rate of morbidity (p = 0.04) but with similar mortality and length of stay. When considering only major liver resections, F patients had a higher probability of posthepatectomy liver failure (LR 6.793, p = 0.009), postoperative bleeding (LR 9.541, p = 0.002) and longer ICU stay (LR 8.666, p = 0.003), with similar rates of bile leak, surgical site infections, length of stay and mortality. Conclusions: Frailty seems to be a solid predictor of posthepatectomy liver failure in patients undergoing major liver resections and is associated with a longer ICU stay. However, mortality and surgical morbidity seem to be comparable between frail and non-frail patients.
- 20 February 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (5) , 512
Open AccessIs Frailty Associated with Worse Outcomes After Major Liver Surgery? An Observational Case–Control Study
Background: The rate of morbidity after liver surgery is estimated at 30% and can be even higher when considering higher-risk subgroups of patients. Frailty is believed to better predict surgical outcomes by showcasing the patient’s ability to withstand major surgical stress and selecting frail ones. Methods: This is a single-centre, observational case–control study on patients diagnosed with liver malignancies who underwent liver resections between 2013 and 2024. The five-item modified Frailty Index (mFI-5) was used to split patients into frail and non-frail. The two groups were compared in terms of preoperative, operative and postoperative outcomes using a chi-squared and logistic regression model. Results: A total of 230 patients were included and split into two groups: non-frail, NF, n = 90, and frail patients, F, n = 140. Overall, F patients had a higher rate of morbidity (p = 0.04) but with similar mortality and length of stay. When considering only major liver resections, F patients had a higher probability of posthepatectomy liver failure (LR 6.793, p = 0.009), postoperative bleeding (LR 9.541, p = 0.002) and longer ICU stay (LR 8.666, p = 0.003), with similar rates of bile leak, surgical site infections, length of stay and mortality. Conclusions: Frailty seems to be a solid predictor of posthepatectomy liver failure in patients undergoing major liver resections and is associated with a longer ICU stay. However, mortality and surgical morbidity seem to be comparable between frail and non-frail patients.